🇺🇸 FDA
Patent

US 8637560

Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment

granted A61KA61K31/4166A61K31/4178

Quick answer

US patent 8637560 (Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Jan 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/4166, A61K31/4178, A61P, A61P31/12